Literature DB >> 8125523

Differential capacity of various anti-Ig reagents to synergize with interleukin-4 to induce clonal expansion in resting and activated B cells.

C Gutiérrez1, E Cabrero.   

Abstract

The regulation of B cell growth responses by cross-linking of surface Ig receptors by monoclonal or polyclonal antibodies and its interaction with interleukin-4 (IL-4) has been evaluated. High-density B cells from autoimmune NZB/W mice were proliferated in the presence of low concentrations of a polyclonal goat anti-mu antibody and IL-4. Similarly, slight but significant positive responses were obtained with anti-K monoclonal antibodies and IL-4. In contrast, the same concentration of other surface Ig binding agents such as monoclonal antibodies against mu and delta immunoglobulin heavy chains did not synergize with IL-4 in order to induce clonal expansion of resting B cells. Polyclonal and monoclonal anti-Ig reagents inhibited the spontaneous cell growth of low-density B cells (in vivo activated B cells), although the negative effect was less noticeable with anti-delta monoclonal antibodies. Upon addition of IL-4 to activated B cell cultures in the presence of goat anti-mu antibody, a significant proliferative response was obtained. However, this lymphokine was unable to induce clonal expansion of B cell blasts in the presence of the various monoclonal anti-Ig antibodies employed in this study. Similar results were obtained with splenic B cells from normal animals, suggesting that the results shown in this report are not due to putative functional peculiarities of autoimmune B cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8125523     DOI: 10.1016/S0171-2985(11)80418-3

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  1 in total

1.  Soluble, but not immobilized, anti-IgM antibody inhibits post-activation events leading to T-cell-dependent B-cell differentiation.

Authors:  J Zamorano; D Rivas; A Gayo; L Mozo; C Gutiérrez
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.